
NVRO
Nevro Corp
- Overview
- Forecast
- Valuation
- Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
37.88M
EV
154.31M
EV/OCF(TTM)
--
P/S(TTM)
0.53
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
100.47M
+3.67%
--
--
102.14M
-1.94%
--
--
92.23M
-9.49%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Nevro Corp. (NVRO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by %.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
9 Analyst Rating

Wall Street analysts forecast NVRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVRO is 5.85 USD with a low forecast of 5.85 USD and a high forecast of 5.85 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
9 Hold
0 Sell
Hold

Current: 0

Low
5.85
Averages
5.85
High
5.85

Current: 0

Low
5.85
Averages
5.85
High
5.85
Canaccord Genuity
William Plovanic
Hold
Maintains
$4 → $5.85
2025-02-07
Reason
Canaccord Genuity
William Plovanic
Price Target
$4 → $5.85
2025-02-07
Maintains
Hold
Reason
Piper Sandler
Adam Maeder
Sell
to
Hold
Upgrades
$6 → $5.85
2025-02-07
Reason
Piper Sandler
Adam Maeder
Price Target
$6 → $5.85
2025-02-07
Upgrades
Sell
to
Hold
Reason
Truist Securities
Richard Newitter
Hold
Maintains
$7 → $4.7
2024-12-18
Reason
Truist Securities
Richard Newitter
Price Target
$7 → $4.7
2024-12-18
Maintains
Hold
Reason
Wells Fargo
Nathan Treybeck
Hold
Maintains
$5 → $4
2024-12-11
Reason
Wells Fargo
Nathan Treybeck
Price Target
$5 → $4
2024-12-11
Maintains
Hold
Reason
Wells Fargo resumed coverage of Nevro with an Equal Weight rating and $5 price target. Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second half of 2025, though the firm does not see upside to Street estimates, the analyst tells investors in a research note. Easier y/y comps, lessened competitive trialing, AdaptivAI ramp, continued healthy growth in painful diabetic neuropathy, adding new sales territories, and Vyrsa ramping could support 2025 growth, the firm says.
Citigroup
Joanne Wuensch
Hold
Maintains
$6 → $5
2024-12-11
Reason
Citigroup
Joanne Wuensch
Price Target
$6 → $5
2024-12-11
Maintains
Hold
Reason
Citi analyst Joanne Wuensch lowered the firm's price target on Nevro to $5 from $6 and keeps a Neutral rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Canaccord Genuity
William Plovanic
Hold
Maintains
$7 → $4
2024-12-09
Reason
Canaccord Genuity
William Plovanic
Price Target
$7 → $4
2024-12-09
Maintains
Hold
Reason
Canaccord lowered the firm's price target on Nevro to $4 from $7 and keeps a Hold rating on the shares. Canaccord said they are bullish on the Med-Tech sector heading into 2025 as they expect investor interest to increase given smid-cap valuations continue to remain depressed while M&A has picked up and the IPO market seems to have opened. They highlight how AI is changing the space and are seeing continued interest in value-based care in the US, and believe that med-tech is well positioned to help drive the trend for improving patient outcomes while also reducing overall costs.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Nevro Corp (NVRO.N) is -2.30, compared to its 5-year average forward P/E of -28.10. For a more detailed relative valuation and DCF analysis to assess Nevro Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-28.10
Current PE
-2.30
Overvalued PE
-1.05
Undervalued PE
-55.15
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-31.57
Current EV/EBITDA
-12.91
Overvalued EV/EBITDA
282.52
Undervalued EV/EBITDA
-345.67
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
5.23
Current PS
0.53
Overvalued PS
9.96
Undervalued PS
0.51
Financials
Annual
Quarterly
FY2024Q3
YoY :
-6.69%
96.91M
Total Revenue
FY2024Q3
YoY :
-40.64%
-15.17M
Operating Profit
FY2024Q3
YoY :
-34.65%
-15.34M
Net Income after Tax
FY2024Q3
YoY :
-36.92%
-0.41
EPS - Diluted
FY2024Q3
YoY :
-102.01%
161.00K
Free Cash Flow
FY2024Q3
YoY :
-1.52%
65.91
Gross Profit Margin - %
FY2024Q3
YoY :
-21.13%
-13.51
FCF Margin - %
FY2024Q3
YoY :
-29.99%
-15.83
Net Margin - %
FY2024Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NVRO News & Events
Events Timeline
2025-04-22 (ET)
2025-04-22
08:30:04
Thirteen option delistings on April 22nd

2025-04-03 (ET)
2025-04-03
08:47:08
Globus Medical completes acquisition of Nevro

2025-03-04 (ET)
2025-03-04
16:18:24
Nevro is not issuing FY25 guidance

Sign Up For More Events
Sign Up For More Events
News
7.0
03-23GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, NVRO, PLYA on Behalf of Shareholders
9.5
03-04PRnewswireNevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
3.0
03-02NASDAQ.COMNEVRO Earnings Preview: Recent $NVRO Insider Trading, Hedge Fund Activity, and More
Sign Up For More News
People Also Watch

GLSI
Greenwich Lifesciences Inc
11.570
USD
+0.70%

MYFW
First Western Financial Inc
23.405
USD
-4.70%

INSG
Inseego Corp
7.360
USD
+1.52%

MED
Medifast Inc
14.900
USD
-1.39%

ACTU
Actuate Therapeutics Inc
7.260
USD
+3.86%

BHR
Braemar Hotels & Resorts Inc
2.380
USD
-0.42%

ABAT
American Battery Technology Co
3.155
USD
-6.38%

LYEL
Lyell Immunopharma Inc
12.420
USD
+19.31%

VXRT
Vaxart Inc
0
USD
-33.44%

INFU
InfuSystem Holdings Inc
6.010
USD
+1.69%
FAQ

What is Nevro Corp (NVRO) stock price today?
The current price of NVRO is 0 USD — it has increased 0 % in the last trading day.

What is Nevro Corp (NVRO)'s business?

What is the price predicton of NVRO Stock?

What is Nevro Corp (NVRO)'s revenue for the last quarter?

What is Nevro Corp (NVRO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Nevro Corp (NVRO)'s fundamentals?

How many employees does Nevro Corp (NVRO). have?
